Figure 3.

Study-specific results for the relative risk of ovarian cancer for current-or-recent users versus never-users of hormone therapy

For study-specific details and references, see appendix pp 7–10. Dotted lines represent totals for all prospective studies and, separately, for all retrospective studies. Study-specific results are arranged by study design and region; results are given for individual studies with the most statistical information (ie, with variance of log relative risk <0·03). Results for the remaining studies are grouped together here (and given separately for every study in appendix p 14). In comparisons of relative risks in prospective versus retrospective studies, overall heterogeneity p<0·0001; for European studies, heterogeneity p=0·4; and for North American studies, heterogeneity p=0·002. In a comparison of relative risks in prospective studies, Europe versus North American heterogeneity p=0·9; for retrospective studies, Europe versus North American heterogeneity p=0·04. References provided in the appendix. *Risk relative to never-users of hormone therapy, stratified by age at diagnosis, study, and body-mass index, and adjusted for age at menopause, hysterectomy, oral contraceptive use, and parity.